Evaxion A/S Files Form 6-K

Ticker: EVAX · Form: 6-K · Filed: 2025-05-22T00:00:00.000Z

Sentiment: neutral

Topics: reporting, foreign-private-issuer

TL;DR

Evaxion A/S filed a 6-K on 5/22/25, confirming it's a foreign private issuer filing 20-F.

AI Summary

Evaxion A/S, a biotechnology company, filed a Form 6-K on May 22, 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Hoersholm, Denmark.

Why It Matters

This filing provides routine updates for investors regarding Evaxion A/S's status as a foreign private issuer and its reporting obligations.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What type of filing is Evaxion A/S submitting?

Evaxion A/S is submitting a Form 6-K, which is a Report of Foreign Private Issuer.

When was this Form 6-K filed?

The Form 6-K was filed on May 22, 2025.

Where is Evaxion A/S's principal executive office located?

Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does Evaxion A/S file its annual reports under Form 20-F or Form 40-F?

Evaxion A/S indicates that it files its annual reports under cover of Form 20-F.

What is the SIC code for Evaxion A/S?

The Standard Industrial Classification (SIC) code for Evaxion A/S is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0001171843-25-003392.txt : 20250522 0001171843-25-003392.hdr.sgml : 20250522 20250522081605 ACCESSION NUMBER: 0001171843-25-003392 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250522 FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25974782 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_052225.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On May 22, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits  Exhibit No.   Description       99.1   Evaxion doses first patient in extens

View on Read The Filing